Trastuzumab seems not only to prevent the dimerization of HER2 with other HER family members and stimulate endocytosis (HER2 internalization), it also appears to play an important role in the tumor microenvironment, implying the feasibility of immunotherapy in HER2-positive malignancies. This evidence concerns the gene ERBB2 and neoplasm.